Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine T- [...]

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement including breast cancer survivors according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium [...]

Choice of surgery may affect quality of life for young breast cancer survivors

Even as more young women with breast cancer opt to have mastectomies many experience a persistent decline in their sexual and psychosocial well-being following the procedure as detailed in new research by Dana-FarberBrigham and Womens Cancer Center The fi [...]

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation

The US Food and Drug Administration approved Xospata gilteritinib for treatment of adult patients who have recurrent or refractory acute myeloid leukemia AML with a FLT3 mutation About Xospata Xospata has demonstrated inhibitory activity against FLT3 inte [...]

Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment

The US Food and Drug Administration FDA on Monday approved a new precision cancer medicine Vitrakvi larotrectinib for the treatment of adult and pediatric solid tumors that have a targetable biomarker known as a neurotrophic receptor tyrosine kinase NTRK [...]

FDA Approves Venclexta Combination for AML in Adults

The Food and Drug Administration granted accelerated approval to Venclexta venetoclax in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia AML in adults who are age 75 years or ol [...]

Patients with rare, incurable digestive tract cancers respond to new drug combination

Dublin Ireland Patients with rare but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways which drive the disease in some cases They have survived for longer without the disease p [...]

Tivozanib for Renal Cell Cancer

The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer RCC About tivozanib Tivozanib is an oral vascular endothelial growth factor VEGF tyrosine kinase inhibitor In the curren [...]

Keytruda Immunotherapy for Treatment of Liver Cancer

According to the results of a study presented at the recent gastrointestinal cancer symposia Keytruda pembrolizumab is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar sorafenib 1 and has not been approv [...]

U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma

The US Food and Drug Administration FDA has approved Empliciti elotuzumab injection for intravenous use in combination with pomalidomide and dexamethasone EPd for the treatment of adult patients with multiple myeloma who have received at least two prior t [...]